{
    "nct_id": "NCT05502237",
    "official_title": "A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
    "inclusion_criteria": "* Life expectancy â‰¥ 3 months.\n* Pathologically documented NSCLC that meets both of the criteria below:\n\n  * Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on American Joint Committee on Cancer (AJCC), Eighth Edition).\n  * Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations.\n* Have no actionable genomic alterations such as ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other driver oncogenes with approved frontline therapies.\n* Have not received prior systemic treatment for metastatic NSCLC.\n* Measurable disease per RECIST v1.1 criteria by investigator assessment.\n* Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.\n* Have adequate organ functions.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have mixed small-cell lung cancer (SCLC) and NSCLC histology.\n* Positive serum pregnancy test or individuals who are breastfeeding or have plans to breastfeed during the study period.\n* Received prior treatment with any anti-PD-1, anti-PD-L1, or any other antibody targeting an immune checkpoint.\n* Known hypersensitivity to the study drug, its metabolites, or formulation excipient.\n* Have an active second malignancy or have had an active second malignancy within 3 years prior to enrollment.\n* Have an active autoimmune disease that required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).\n* Are receiving chronic systemic steroids.\n* Have significant third-space fluid retention.\n* Have untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrollment.\n* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Has had an allogenic tissue/solid organ transplant.\n* Have received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.\n* Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}